Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | PLK1 | P53350 | 1/20 | 0.76 |
| ▸ | ALPL | P05186 | 3/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982068 | 0.87 | MAPT (0.76) | MAPTSMN1; SMN2PLK1ALPLCA9 | |
| SCHEMBL11962149 | 0.86 | PLK1 (1.00) | MAPTSMN1; SMN2PLK1ALPLCA9 | |
| SCHEMBL14152359 | 0.84 | ALPL (1.00) | MAPTSMN1; SMN2ALPLCA9TP53 | |
| SCHEMBL14152213 | 0.83 | TP53 (0.61) | MAPTSMN1; SMN2PLK1ALPLCA9 | |
| SCHEMBL4714286 | 0.83 | MAPT (0.77) | MAPTSMN1; SMN2PLK1ALPLTP53 | |
| SCHEMBL12172055 | 0.81 | MAPT (0.60) | MAPTSMN1; SMN2PLK1ALPLCA9 | |
| SCHEMBL31178157 | 0.81 | TP53 (0.71) | SMN1; SMN2ALPLCA9TP53CA12 | |
| SCHEMBL726574 | 0.80 | TP53 (1.00) | SMN1; SMN2ALPLCA9TP53CA12 | |
| SCHEMBL14152904 | 0.78 | MAPT (0.77) | MAPTSMN1; SMN2ALPLCA9TP53 | |
| SCHEMBL28357149 | 0.78 | TP53 (0.55) | MAPTSMN1; SMN2PLK1ALPLCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596567-B | Pyrazole derivatives | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-16 | — | — | CN | disclosed |
| EP-2717873-B1 | PYRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-9073911-B2 | Pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2717873-A1 | PYRAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| CN-103596567-A | Pyrazole derivatives | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | disclosed |
| US-20120316172-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2012168260-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009143150-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | MAPT 4675/4885SMN1; SMN2 4353/4885PLK1 1726/4885 |
| US-20120316172-A1 | PYRAZOLE DERIVATIVES | TAAR1, TAAR5, NPY1R | MAPT 230/4885SMN1; SMN2 3130/4885PLK1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.